MOTS-c and Weight Loss: What Studies Report

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a short peptide encoded inside mitochondrial DNA rather than in the nuclear genome. Review articles have described it as one of a small family of mitochondrial-derived peptides that appear to act as signalling molecules between the mitochondrion and the rest of the cell, with reported involvement in metabolic regulation, stress responses and aging biology (PMID 36233287, PMID 36670507). This page summarises what the published literature reports about MOTS-c in relation to body composition and metabolism, and where the evidence stops.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, medication or investigational compound. Nothing here describes a protocol, and no dosing schedules are reproduced.

Why MOTS-c became associated with body weight at all

The link between MOTS-c and adiposity traces mainly to one influential preclinical paper. In a 2015 study published in Cell Metabolism, researchers reported that MOTS-c targeted skeletal muscle, interfered with the folate cycle and its linked de novo purine biosynthesis pathway, and led to accumulation of the AMPK-activating intermediate AICAR (PMID 25738459). In the same report, MOTS-c treatment in mice was described as preventing age-dependent insulin resistance, high-fat-diet-induced insulin resistance, and diet-induced obesity.

Those three findings — insulin sensitivity, glucose handling and reduced diet-induced fat gain in rodents — are the origin of nearly every popular claim about MOTS-c and weight. It is worth being precise about what the study design allowed: it was an animal and cell-based investigation, the obesity outcome was framed as prevention of diet-induced weight gain rather than reversal of established obesity in humans, and outcome measures were laboratory endpoints such as body weight, fat mass and insulin sensitivity in mice (PMID 25738459).

What the animal literature reports

Metabolic and glucose models

Subsequent rodent work extended the metabolic theme. In a 2022 study in Pharmacological Research, researchers reported that MOTS-c relieved hyperglycemia and insulin resistance in a model of gestational diabetes mellitus (PMID 34798268). A 2023 review in Metabolites collected animal and cell findings under the heading that MOTS-c "functionally prevents metabolic disorders," summarising reported effects on insulin sensitivity, glucose uptake and lipid handling across models (PMID 36677050). A separate 2023 review in the Journal of Translational Medicine grouped the same literature around stress signalling, metabolism and aging, and noted that MOTS-c biology has been studied in exercise and metabolic-stress contexts (PMID 36670507).

Skeletal muscle and lipid infiltration

Body composition is not the same thing as body weight, and some of the more recent animal work addressed muscle rather than fat mass. A 2024 study in the American Journal of Physiology — Endocrinology and Metabolism used an immobilization model and reported that MOTS-c attenuated immobilization-induced skeletal muscle atrophy, with the authors attributing the effect to suppression of lipid infiltration into muscle tissue (PMID 38170165). A 2024 mechanistic paper in iScience reported that MOTS-c directly bound and activated casein kinase 2 (CK2), and that this interaction modulated skeletal muscle function (PMID 39559755).

These two reports are frequently cited in consumer discussions as evidence of "body recomposition," but neither was a weight-loss experiment. One examined disuse atrophy and intramuscular fat; the other identified a molecular binding partner in muscle (PMID 38170165, PMID 39559755).

Study designs at a glance

What human data exist

The most important limit for anyone reading claims about MOTS-c and weight is that the human literature is largely observational. Reviews describe measurements of circulating MOTS-c concentrations in people and their associations with age, metabolic status and exercise, rather than trials in which MOTS-c was given to participants and body composition was measured against placebo (PMID 36233287, PMID 36670507).

Association studies of this type cannot separate cause from consequence. If people with better metabolic health show different circulating MOTS-c levels, the peptide could be a driver, a marker, or both — and reviews of the field have repeatedly framed clinical translation as an open task rather than a completed one (PMID 36761202). As of the papers summarised here, no published randomized controlled trial has tested MOTS-c administration in humans with body weight or fat mass as a primary outcome.

Doses and administration in the published work

Dose, route and duration in the studies above were experimental parameters chosen for specific animal models, and this page does not reproduce them as figures, because doing so invites misreading as instruction. What can be said neutrally is that the rodent studies administered MOTS-c systemically over defined experimental periods and measured laboratory endpoints afterwards (PMID 25738459, PMID 38170165). Rodent dosing does not convert to human dosing by simple arithmetic, and reviews of the field have not established a human dose range for any indication (PMID 36761202).

Wider MOTS-c research, and why it matters for interpretation

MOTS-c has been investigated well beyond metabolism, which is a useful reminder that a peptide with broad signalling activity is not a targeted weight intervention. Published reports include effects on ovarian cancer progression through a USP7–LARS1 deubiquitination pathway (PMID 39321430), an antiviral role during hepatitis B virus infection linked to mitochondrial remodelling (PMID 37788894), a MOTS-c-dependent mechanism in radiation-induced lung injury studied alongside pyrroloquinoline quinone (PMID 39259217), and participation in plasma membrane repair by facilitating translocation of TRIM72 to the membrane (PMID 39267782).

Findings in one tissue or disease model do not transfer to another. A peptide reported to influence tumour signalling, viral replication and membrane repair in laboratory systems is a molecule whose full physiological consequences in humans have not been mapped (PMID 39321430, PMID 37788894).

How to read the evidence critically

• Prevention is not reversal. The landmark obesity finding described prevention of diet-induced weight gain in mice, not reduction of established human adiposity (PMID 25738459).
• Species matters. Rodent energy metabolism, thermoregulation and diet models differ substantially from human free-living conditions, a point reviews raise when discussing translation (PMID 36761202).
• Endpoint matters. Insulin sensitivity, glucose tolerance, muscle mass and intramuscular lipid are distinct outcomes, and the studies above measured different ones (PMID 34798268, PMID 38170165).
• Reviews are not trials. Several of the most-cited MOTS-c sources are narrative reviews that aggregate preclinical work; they do not add new human outcome data (PMID 36233287, PMID 36677050).
• Absence of human trials is itself information. Where randomized data are missing, effect sizes, response rates and time courses in people are unknown.

Safety and Adverse Events: What Studies Report

The published MOTS-c literature summarised here is dominated by mechanism and efficacy endpoints in animals and cells; it does not contain human safety datasets of the kind generated by phase I trials. Reviews of MOTS-c in aging and age-related disease and of its therapeutic prospects discussed the peptide as an investigational target and did not report an established human adverse-event profile or tolerability range (PMID 36233287, PMID 36761202). The animal studies cited above reported metabolic and muscle outcomes rather than systematic toxicology (PMID 25738459, PMID 38170165).

Because MOTS-c has been reported to act on pathways involved in cell growth, viral replication and membrane integrity in laboratory models, reviewers have treated long-term consequences in humans as unresolved rather than reassuring (PMID 39321430, PMID 37788894). Any statement that MOTS-c is "well tolerated" in people is not supported by the papers listed on this page.

Regulatory status

MOTS-c is not an approved drug product in the United States or the European Union for obesity, diabetes or any other indication. Material sold under the name is typically labelled for research use only, which is a laboratory designation and not a statement of human safety or efficacy. This section describes regulatory facts and is not legal advice.

Open questions the literature has not answered

1. Whether exogenous MOTS-c changes fat mass or body weight in humans under controlled conditions, and by how much.
2. Whether the AMPK-linked mechanism reported in mouse skeletal muscle operates comparably in human muscle (PMID 25738459, PMID 39559755).
3. Whether observed associations between circulating MOTS-c and metabolic status reflect causation (PMID 36670507).
4. What human pharmacokinetics, durability of effect and safety margins look like, none of which the cited reviews establish (PMID 36761202).

Readers comparing marketing language against the record will notice a gap: the strongest metabolic claims rest on a 2015 mouse study and its mechanistic descendants, while human evidence remains correlational (PMID 25738459, PMID 36233287).

References

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (International Journal of Molecular Sciences, 2022)
• Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Journal of Translational Medicine, 2023)
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• MOTS-c Functionally Prevents Metabolic Disorders (Metabolites, 2023)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology. Endocrinology and Metabolism, 2024)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
• Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane (Theranostics, 2024)